PBAC Public Summary Documents - August 2019
Page last updated: 30 April 2020
Public Summary Documents relating to the August 2019 PBAC meeting.
- Antibiotic Repeats on the Pharmaceutical Benefits Scheme
- Broad PBS subsidy listing for PD-(L)1 checkpoint inhibitors for non-small cell lung cancer
- Dolutegravir with Lamivudine, Tablet containing dolutegravir 50 mg (as sodium) with lamivudine 300 mg, Dovato®, ViiV Health Care Pty Ltd
- Ferric Derisomaltose Injection 1000 mg (iron) in 10 mL, Injection 500 mg (iron) in 5 mL, Monofer®, Pfizer Australia Pty Ltd.
- Influenza Quadrivalent Adjuvanted Vaccine, Injection 0.5 mL Fluad® Quad, and Influenza Trivalent Adjuvanted Vaccine, Injection 0.5 mL, Fluad®, Seqirus (Australia) Pty Ltd
- Lenalidomide, 5 mg, 10 mg, 15 mg, 25 mg, Capsule, Revlimid®, Celgene Pty Ltd.
- Risperidone 500 microgram and 1 mg tablet, 1mg/mL oral liquid, Various Sponsors
- Somatropin All forms and strengths, All brands
The following Public Summary Document has been updated.
